{
    "clinical_study": {
        "@rank": "149556", 
        "arm_group": [
            {
                "arm_group_label": "PACLITAXEL", 
                "arm_group_type": "Active Comparator", 
                "description": "PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY"
            }, 
            {
                "arm_group_label": "NAB-PACLITAXEL", 
                "arm_group_type": "Experimental", 
                "description": "NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and\n      carboplatin with concurrent radiation in local-regionally advanced lung cancer. There are no\n      published human studies combining Nab-Paclitaxel (Abraxane) with radiation.  The\n      investigators will first confirm the tolerated dose (TD) of concurrent Nab-Paclitaxel\n      (Abraxane) at 50mg/m2, and then will begin enrolling patients into the phase II component\n      using either Nab-Paclitaxel (Abraxane) at the TD with carboplatin concurrent with daily\n      radiation or paclitaxel with with carboplatin concurrent with daily radiation."
        }, 
        "brief_title": "A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically documented NSCLC; Patients must be M0. Patients with\n             T1-T2 with N2 or T3N1-2 are eligible, if inoperable.  Patients with T4 with any N or\n             any T with N2 or N3 disease are eligible if unresectable.\n\n          -  Patients with tumors adjacent to a vertebral body are eligible as long as all gross\n             disease can be encompassed in the radiation boost field.  The boost volume must be\n             limited to < 50% of the ipsilateral lung volume.\n\n          -  Patients with Zubrod performance status 0-1\n\n          -  Adequate hematologic function\n\n          -  FEV1 with \u2265 1200 cc or \u2265 50% predicted\n\n        Exclusion Criteria:\n\n          -  Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for\n             any reason and/or surgical resection of present cancer\n\n          -  Exudative, bloody, or cytologically malignant effusions\n\n          -  Prior therapy with any molecular targeted drugs (for lung cancer)\n\n          -  Active pulmonary infection not responsive to conventional antibiotics\n\n          -  Clinically significant cardiovascular event (e.g. myocardial infarction, superior\n             vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart\n             disease >2 (see Appendix B) within 3 months before entry; or presence of cardiac\n             disease that, in the opinion of the Investigator, increases the risk of ventricular\n             arrhythmia.\n\n          -  Patients with > grade 1 neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "98", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757288", 
            "org_study_id": "STU 062012-053"
        }, 
        "intervention": [
            {
                "arm_group_label": "NAB-PACLITAXEL", 
                "intervention_name": "NAB-PACLITAXEL", 
                "intervention_type": "Drug", 
                "other_name": "Abraxan"
            }, 
            {
                "arm_group_label": "PACLITAXEL", 
                "intervention_name": "PACLITAXEL", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "INOPERABLE LUNG CANCER", 
            "STAGE IIIA/B NON-SMALL CELL LUNG CANCER"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75239"
                }, 
                "name": "University of Texas Southwestern Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)", 
        "overall_contact": {
            "last_name": "Hak Choy, MD", 
            "phone": "214-645-8525"
        }, 
        "overall_contact_backup": {
            "last_name": "Jean Wu, MSN", 
            "phone": "214-633-1753"
        }, 
        "overall_official": {
            "affiliation": "University of Texas Southwestern Medical Center", 
            "last_name": "Hak Choy, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "2-year overall survival from randomization for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757288"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety is measured by the rate of grade 3 or higher radiation related esophagitis or pulmonary toxicity or chemotherapy related grade 4 hematological or other non-hematological toxicities occurring within 60 days of the start of treatment; compliance is defined as the completion of the treatment regimen with no more than minor variations.", 
                "measure": "the feasibility of concurrent carboplatin/nab-paclitaxel and radiation therapy", 
                "safety_issue": "Yes", 
                "time_frame": "60 days of the start of treatment"
            }, 
            {
                "measure": "overall response rate for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "the progression-free survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "the median overall survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "quality of life (QOL) of patients receiving either nab-paclitaxel or paclitaxel when given with concurrent radiotherapy", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "correlate outcomes (survival, toxicity, QOL) with biological parameters", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }
        ], 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}